Opdivo (Nivolumab) 10mg/10ml

What is Opdivo (nivolumab) for?

Opdivo (nivolumab) is indicated for the treatment of patients with:

    metastatic melanoma as a single agent or in combination with ipilimumab

    metastatic non-small cell lung cancer (NSCLC) whose cancer progressed on or after chemotherapy

    advanced renal cell carcinoma who have received prior anti-angiogenic therapy

    classical Hodgkin lymphoma that has relapsed or progressed after other treatment.

    recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or within 6 months of receiving platinum-based chemotherapy

    locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy[10]

    microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan

    hepatocellular carcinoma in patients who have been previously treated with sorafenib
    for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).

How does Opdivo (nivolumab) work?

Opdivo (nivolumab) has been designed to attach to a receptor called PD-1, found on certain cells of the immune system called T cells. Cancer cells can produce proteins (PD-L1 and PD-L2) that attach to this receptor, switching off the T cells. By attaching to the receptor, nivolumab prevents cancer cells from switching off T cells, thereby increasing the ability of the immune system to kill cancer cells.